字号·· | 护眼
彭博社

生物技术风投公司Flagship向英国新实验室投资1亿英镑Biotech Venture Firm Flagship Invests £100 Million in New UK Lab

点「原文对照」整页切到原文,或双击某段只看那段的原文。

孵化出 Moderna Inc. 的生物技术风投公司 Pioneering 正在拓展版图,将在美国以外设立首个全规模基地。

Pioneering, the biotech venture firm that brought the world Moderna Inc., is expanding its footprint with its first full-scale site outside the US.

这家生命科学投资公司在一份声明中表示,将在未来几年投入 1 亿英镑,在伦敦建设一个实验室,该实验室将“构想、测试、资助并孵化”专注于人类健康、环境科学和农业领域的 AI 生物技术公司。Pioneering 计划通过尚未公布的合作伙伴关系,为新实验室再引入 5 亿英镑资金。

The life sciences investment firm will commit £100 million over the next few years to build out a London-based lab that “will conceive, test, fund and build” AI-focused biotech firms in human health, environmental science and agriculture, the company said in a statement. Flagship plans to bring in an additional £500 million in funding for the new lab through yet-to-be announced partnerships.

首席执行官 Noubar Afeyan 在采访中表示,该风投公司将在伦敦现有十几名员工的基础上,再增加 50 名科学家兼企业家及公司运营人员,目标是在未来几年建立 8 到 10 家总部设在英国的生物技术公司。其中一些将专注于类似 Moderna 的广泛平台技术,另一些则将聚焦单一药物资产。

The venture firm will add 50 scientist-entrepreneurs and company operators to the roughly dozen people it already has in London, with the goal of establishing 8 to 10 new UK-based biotechs over the next few years, Chief Executive Officer Noubar Afeyan said in an interview. Some will focus on broad platform technologies, like Moderna does, while others will be centered on single drug assets.

Afeyan 在采访中说:“我们的目标是建立一个公司生态系统”,这些公司既能互助发展,又能利用 Pioneering 在波士顿打造的能力。这位亿万富翁兼生化工程师表示,他之所以选择伦敦,是因为这里拥有世界一流的生物医学研究基础设施、深厚的 AI 专业知识和强大的临床能力。

“Our goal is to establish an ecosystem of companies” that can help each other develop while also leveraging the capabilities that Flagship has created in Boston, Afeyan said in the interview. The billionaire and biochemical engineer said he was attracted to London because of its world-class biomedical research infrastructure, deep AI expertise and strong clinical capabilities.

“英国是人工智能和生命科学公司的天然家园,我们希望看到更多这些领域的新企业将前沿研究和技术转化为新的就业岗位和经济增长,”英国科学、创新和投资大臣克里斯·麦克唐纳在一份声明中说。“Flagship Pioneering 的这项新承诺将在英国启动未来的公司。”

“The UK is a natural home for AI and life sciences companies, and we want to see more new businesses across these sectors turning cutting-edge research and technology into new jobs and economic growth,” Chris McDonald, UK minister for science, innovation and investment said in a statement. “This new commitment from Flagship Pioneering will kick-start companies of the future in the UK.”

Flagship 在创建生物技术公司方面采取了一种非同寻常的方法。与大多数风投公司不同,该公司并不将大部分资金用于开发他人的想法。相反,其大约 600 名员工提出自己的概念,这些概念通常由 Flagship 资助数年,然后再引入外部投资者。

Flagship takes an unusual approach to the creation of biotechs. Unlike most venture firms, the company doesn’t spend most of its money developing other peoples’ ideas. Instead, its roughly 600 employees come up with their own concepts that are often funded by Flagship for years before bringing in outside investors.

Moderna 是 Flagship 最大的成功案例,曾因利用 mRNA 技术帮助开创新冠疫苗而闻名。8 月,Moderna 及其合作伙伴默克公司宣布,双方针对一种致命皮肤癌的 mRNA 疫苗在最终阶段试验中取得成功。这一里程碑有可能为广泛的新型癌症疫苗领域铺平道路,未来或许有助于治疗多种肿瘤。Moderna 的股价今年上涨了 600% 以上。

Moderna, Flagship’s biggest success story, famously helped pioneer Covid-19 vaccines using mRNA technology. In August, Moderna and its partner Merck & Co. announced that the companies’ mRNA vaccine for a deadly form of skin cancer had succeeded in a final-stage trial. That milestone could potentially pave the way for a broad new field of cancer vaccines that could someday help treat numerous tumors. Moderna’s shares are up more than 600% this year.

这一举措标志着这家总部位于马萨诸塞州剑桥市的公司发生了根本性转变,此前其旗下 130 多家公司几乎全部设在波士顿地区。在过去 25 年里,该公司一直是波士顿地区跻身全球生命科学中心的关键力量。该公司及其关联企业在波士顿、剑桥及周边城镇占据了 300 多万平方英尺的空间,相当于该地区目前已使用实验室空间的近 9%。

The initiative marks a sea change for a firm that’s headquartered nearly every one of its 130-plus companies in the Boston area. The Cambridge, Massachusetts-based company has been a key part of the Boston area’s elevation into a global life sciences hub over the past quarter-century. The firm and its related companies occupy more than 3 million square feet in Boston, Cambridge and neighboring towns, equal to nearly 9% of the area’s currently used lab space.

不过,这种光环略有黯淡,因为马萨诸塞州去年几十年来首次出现生物制药就业岗位下降。但阿费扬表示,Flagship “在波士顿做得更多、效率更高,超过了以往”,并称依然致力于该地区。

That luster has dimmed slightly, as Massachusetts experienced a decline in biopharmaceutical jobs for the first time in decades last year. But Afeyan said that Flagship is “doing more, more efficiently, in Boston than we have before,” and that it remains committed to the region.

首席执行官未提供向伦敦实验室追加5亿英镑资金的时间表,但补充称,“这是我们正在与多家合作伙伴非常积极地推进的事情。”

The chief executive didn’t provide a timeline for the additional £500 million in funding for the London lab, but added that “it’s something that we’re working very actively with a number of partners on.”

阅读媒体原文 ↗